Insmed Incorporated
INSM
Classement en actions
#1109
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Prix de l'action
$95.88
Capitalisation boursière
$20.94B
Changement (1 jour)
0.61%
Changement (1 an)
-42.90%
Pays
US
Échange Insmed Incorporated (INSM)
Catégorie
Healthcare
Ratio P/B pour Insmed Incorporated (INSM)
Ratio P/B au October 2026 TTM : 28.06
Selon les derniers rapports financiers et le cours de l'action de Insmed Incorporated, le ratio cours/valeur comptable actuel (TTM) est 28.06. À la fin de 2023, le ratio P/B était de -13.11.
Historique du ratio P/B pour Insmed Incorporated de 2000 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 28.06 | -29.30% |
| 2024 | 39.69 | -402.68% |
| 2023 | -13.11 | -146.91% |
| 2022 | 27.95 | 275.67% |
| 2021 | 7.44 | -36.83% |
| 2020 | 11.78 | 52.62% |
| 2019 | 7.72 | 59.41% |
| 2018 | 4.84 | -15.80% |
| 2017 | 5.75 | 8.54% |
| 2016 | 5.30 | 55.48% |
| 2015 | 3.41 | -4.67% |
| 2014 | 3.57 | -13.87% |
| 2013 | 4.15 | 182.67% |
| 2012 | 1.47 | 176.73% |
| 2011 | 0.53 | 22.38% |
| 2010 | 0.43 | -45.13% |
| 2009 | 0.79 | -103.91% |
| 2008 | -20.23 | -345.58% |
| 2007 | 8.24 | 36.28% |
| 2006 | 6.04 | -33.73% |
| 2005 | 9.12 | -23.38% |
| 2004 | 11.90 | 195.16% |
| 2003 | 4.03 | 549.88% |
| 2002 | 0.62 | -70.50% |
| 2001 | 2.10 | 220.36% |
| 2000 | 0.66 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | -77.72% |
US
|
|
| 13.2547 | -52.76% |
US
|
|
| 4.208 | -85.00% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -77.97% |
NL
|
